 |
Journal articles
A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques
Patrycja Nzounza
1, 2
Grégoire Martin
2
Nathalie Dereuddre-Bosquet
3
Valérie Najburg
4
Leslie Gosse
3
Claude Ruffié
4
Chantal Combredet
4
Caroline Petitdemange
2
Sylvie Souquère
1
Géraldine Schlecht-Louf
5
Christiane Moog
6, 7
Gérard Pierron
1
Roger Le Grand
3
Thierry Heidmann
1, *
Frédéric Tangy
4, *
*
Corresponding author
Patrycja Nzounza 1, 2
Author
Grégoire Martin 2
Author ORCID : https://orcid.org/0000-0001-8240-6108
Nathalie Dereuddre-Bosquet 3
Author ORCID : https://orcid.org/0000-0001-6682-6313
Valérie Najburg 4
Author
Leslie Gosse 3
Author
Claude Ruffié 4
Author
Chantal Combredet 4
Author IdHAL : chantal-combredet ORCID : https://orcid.org/0000-0002-2161-199X
Caroline Petitdemange 2
Author
Sylvie Souquère 1
Author
Géraldine Schlecht-Louf 5
Author ORCID : https://orcid.org/0000-0002-7924-5371
Christiane Moog 6, 7
Author ORCID : https://orcid.org/0000-0002-0916-156X
Gérard Pierron 1
Author
Roger Le Grand 3
Author
Thierry Heidmann 1
Correspondent author ORCID : https://orcid.org/0000-0002-9055-1687
Frédéric Tangy 4
Correspondent author ORCID : https://orcid.org/0000-0002-5937-5654
1
RETRO-ENDO - Physiologie et physiopathologie des rétrovirus endogènes et infectieux (39 rue Camille Desmoulins, 94805, Villejuif cedex - France)
- IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France)
- Université Paris-Saclay (Espace Technologique, Bat. Discovery - RD 128 - 2e ét., 91190 Saint-Aubin - France)
- CNRS - Centre National de la Recherche Scientifique : UMR 9196 (France)
2
VIROxIS [Villejuif] (France)
- IGR - Institut Gustave Roussy (114, rue Édouard-Vaillant 94805 Villejuif Cedex -France - France)
3
IMVA-HB - Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (18 route du Panorama, 92265, Fontenay-aux-Roses cedex - France)
- CEA - Commissariat à l'énergie atomique et aux énergies alternatives (Centre de Saclay Centre de Grenoble Centre de Cadarache etc - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U 1184 (101, rue de Tolbiac, 75013 Paris - France)
- Université Paris-Saclay (Espace Technologique, Bat. Discovery - RD 128 - 2e ét., 91190 Saint-Aubin - France)
4
Génomique virale et vaccination (Département de Virologie, 25-28 rue Du Dr Roux, 75724 Paris Cedex 15 - France)
- Institut Pasteur [Paris] (25-28, rue du docteur Roux, 75724 Paris cedex 15 - France)
- CNRS - Centre National de la Recherche Scientifique : UMR3569 (France)
5
MI2 - Inflammation, microbiome, immunosurveillance (5 rue Jean-Baptiste Clément, 92290, Châtenay-Malabry - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : UMR 996 (101, rue de Tolbiac, 75013 Paris - France)
- Université Paris-Saclay (Espace Technologique, Bat. Discovery - RD 128 - 2e ét., 91190 Saint-Aubin - France)
6
FMTS - Fédération de Médecine Translationnelle de Strasbourg (EA 3072 - France)
- UNISTRA - Université de Strasbourg (4 rue Blaise Pascal - CS 90032 - 67081 Strasbourg cedex - France)
7
Immuno-Rhumatologie Moléculaire (1 Place de l'Hôpital 67000 Strasbourg - France)
- UNISTRA - Université de Strasbourg : UMRS1109 (4 rue Blaise Pascal - CS 90032 - 67081 Strasbourg cedex - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U1109 (101, rue de Tolbiac, 75013 Paris - France)
Abstract : Abstract Replicative vectors derived from live-attenuated measles virus (MV) carrying additional non-measles vaccine antigens have long demonstrated safety and immunogenicity in humans despite pre-existing immunity to measles. Here, we report the vaccination of cynomolgus macaques with MV replicative vectors expressing simian-human immunodeficiency virus Gag, Env, and Nef antigens (MV-SHIV Wt) either wild type or mutated in the immunosuppressive (IS) domains of Nef and Env antigens (MV-SHIV Mt). We found that the inactivation of Nef and Env IS domains by targeted mutations led to the induction of significantly enhanced post-prime cellular immune responses. After repeated challenges with low doses of SHIV-SF162p3, vaccinees were protected against high viremia, resulting in a 2-Log reduction in peak viremia, accelerated viral clearance, and a decrease -even complete protection for nearly half of the monkeys- in reservoir cell infection. This study demonstrates the potential of a replicative viral vector derived from the safe and widely used measles vaccine in the development of a future human vaccine against HIV-1.
Document type :
Journal articles
Domain :
Complete list of metadata
https://hal-pasteur.archives-ouvertes.fr/pasteur-03421041
Contributor : Chantal Combredet Connect in order to contact the contributor
Submitted on : Tuesday, November 9, 2021 - 3:09:01 PM
Last modification on : Monday, November 15, 2021 - 10:15:05 AM
Contributor : Chantal Combredet Connect in order to contact the contributor
Submitted on : Tuesday, November 9, 2021 - 3:09:01 PM
Last modification on : Monday, November 15, 2021 - 10:15:05 AM
Licence
Distributed under a Creative Commons Attribution 4.0 International License
Identifiers
- HAL Id : pasteur-03421041, version 1
- DOI : 10.1038/s41541-021-00385-6
- PUBMED : 34686669
- PUBMEDCENTRAL : PMC8536681
Collections
PASTEUR | CEA | FNCLCC | SITE-ALSACE | ANR | CEA-UPSAY | GS-LIFE-SCIENCES-HEALTH | GS-HEALTH-DRUG-SCIENCES | CNRS | INSERM
Citation
Patrycja Nzounza, Grégoire Martin, Nathalie Dereuddre-Bosquet, Valérie Najburg, Leslie Gosse, et al.. A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques. NPJ vaccines, Nature Research 2021, 6 (1), pp.123. ⟨10.1038/s41541-021-00385-6⟩. ⟨pasteur-03421041⟩
Metrics
Record views
35
Files downloads